Teladoc Health (NYSE:TDOC) Raised to “Outperform” at Credit Suisse Group

Share on StockTwits

Credit Suisse Group upgraded shares of Teladoc Health (NYSE:TDOC) from a neutral rating to an outperform rating in a report published on Monday, Benzinga reports. They currently have $249.00 price target on the health services provider’s stock, up from their previous price target of $225.00.

TDOC has been the topic of a number of other research reports. Canaccord Genuity boosted their price objective on Teladoc Health from $195.00 to $255.00 and gave the stock a buy rating in a research report on Thursday, July 30th. CSFB boosted their price objective on Teladoc Health from $152.00 to $165.00 and gave the stock a neutral rating in a research report on Thursday, April 30th. Cantor Fitzgerald boosted their price objective on Teladoc Health from $165.00 to $210.00 and gave the stock a neutral rating in a research report on Thursday, July 30th. Deutsche Bank reduced their price objective on Teladoc Health from $238.00 to $225.00 and set a buy rating on the stock in a research report on Thursday, August 6th. Finally, Stifel Nicolaus boosted their price objective on Teladoc Health from $144.00 to $205.00 and gave the stock a hold rating in a research report on Thursday, July 30th. Fourteen research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Teladoc Health presently has a consensus rating of Buy and an average target price of $202.67.

Teladoc Health stock opened at $218.41 on Monday. The company has a debt-to-equity ratio of 0.73, a current ratio of 11.36 and a quick ratio of 11.36. Teladoc Health has a 52 week low of $54.58 and a 52 week high of $253.00. The stock has a fifty day moving average of $213.70 and a 200-day moving average of $169.80.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.11). Teladoc Health had a negative return on equity of 9.54% and a negative net margin of 13.22%. The business had revenue of $241.03 million for the quarter, compared to analyst estimates of $220.49 million. During the same period last year, the firm posted ($0.41) EPS. Teladoc Health’s quarterly revenue was up 85.0% on a year-over-year basis. On average, sell-side analysts anticipate that Teladoc Health will post -1.42 earnings per share for the current fiscal year.

In other news, SVP Andrew Turitz sold 2,778 shares of the stock in a transaction that occurred on Friday, June 19th. The stock was sold at an average price of $200.00, for a total value of $555,600.00. Following the completion of the sale, the senior vice president now directly owns 6,793 shares of the company’s stock, valued at $1,358,600. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Jason N. Gorevic sold 30,000 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $245.96, for a total value of $7,378,800.00. Following the completion of the sale, the chief executive officer now directly owns 697,283 shares of the company’s stock, valued at $171,503,726.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 180,717 shares of company stock worth $36,994,032. 3.42% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the company. Cullen Frost Bankers Inc. purchased a new stake in shares of Teladoc Health in the second quarter worth approximately $99,000. James Investment Research Inc. purchased a new stake in shares of Teladoc Health in the first quarter worth approximately $71,000. Clear Street Markets LLC raised its stake in shares of Teladoc Health by 66.7% in the first quarter. Clear Street Markets LLC now owns 10,000 shares of the health services provider’s stock worth $1,550,000 after purchasing an additional 4,000 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Teladoc Health by 220.7% in the first quarter. Janney Montgomery Scott LLC now owns 16,437 shares of the health services provider’s stock worth $2,548,000 after purchasing an additional 11,312 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Teladoc Health by 828.4% in the first quarter. AQR Capital Management LLC now owns 76,640 shares of the health services provider’s stock worth $11,880,000 after purchasing an additional 68,385 shares during the last quarter. 97.14% of the stock is owned by hedge funds and other institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Featured Article: Moving Average Convergence Divergence (MACD)

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply